Mechanisms of cartilage destruction and novel nonsurgical therapeutic strategies to retard cartilage injury in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 9, Issue 3, 1997, Pages 241-250

  Hauselmann H J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD5 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTEGRIN; LEUKOTRIENE; METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROSTAGLANDIN; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CARTILAGE CELL; CARTILAGE DEGENERATION; DISEASE ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; PANNUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CYTOKINES; HUMANS; JOINTS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 0030960192     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199705000-00011     Document Type: Review

References (88)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996, 39:712-722.
2. Gordon DA, Hastings DE: Rheumatoid arthritis and spondyloarthropathy, clinical features: early, progressive and late disease. In Rheumatology. Edited by Klippel JH, Dieppe PA. London: Times Mirror International Publishers; 1994:4.1-4.14.
3. Brook A, Corbett M: Radiographic changes in early RA. Ann Rheum Dis 1977, 36:71-73.
4. Fuchs HA, Kaye JJ, Callahan LF, Nace EP, Pincus TP: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989, 16:585-591.
5. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van't Hof MA, van Rijswijk MH, van de Putte LB: Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-34.
6. Woessner JF Jr, Howell DS: Joint Cartilage Degradation: Basic and Clinical Aspects. New York: Marcel Dekker; 1993.
7. Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC: Articular Cartilage and Osteoarthritis. New York: Raven Press; 1992.
8. Barland P, Novikoff AB, Hamerman D: Electron microscopy of the human synovial membrane. J Cell Biol 1962, 14:207-216.
9. Jalkanen S: Leukocyte-endothelial cell interaction and the control of leukocyte migration into inflamed synovium. Springer Semin Immunopathol 1989, 11:187-198.
10. Van Dinther-Janssen ACHM, Pals ST, Scheper R, Breedveld F, Meijer CJLM: Dendritic cells and high endothelial venules in the rheumatoid synovial membrane. J Rheumatol 1990, 17:11-17.
11. Wacholtz MC, Patel SS, Lipsky PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med 1989, 170:431-438.
12. Ridley MG, Kingsley G, Pitzalis C, Panayi GS: Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints. Br J Rheumatol 1990, 29:84-88.
13. Folkman J, Ausprunk D, Langer R: Connective tissue, small blood vessels and capillaries. In Textbook of Rheumatology, edn 2. Edited by Kelley WN. Philadelphia: WB Saunders; 1985:197-210.
14. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987, 235:44-47.
15. Krane SM, Goldring SR, Dayer JM: Interactions among lymphocytes, monocytes and other synovial cells in the rheumatoid synovium. Lymphokines 1982, 7:75-87.
16. Palmer RM, Hikery MS, Charles IG, Moncada S, Bayliss MT: Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993, 193:398-405.
17. Zvaifler NJ, Firestein GS: Pannus and pannocytes: alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994, 37:783-789.
18. Müller Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996, 149:1607-1615.
19. Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA: Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J Biol Chem 1996, 271:23577-23581.
20. Häuselmann HJ, Flechtenmacher J, Michal L, Thonar EJ-MA, Shinmei M, Kuettner KE, Aydelotte MB: The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1996, 39:478-488.
21. Häuselmann HJ, Oppliger L, Michel BA, Stefanovic-Racic M, Evans CH: Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture. FEBS Lett 1994, 352:361-364.
22. Frenkel SF, Clancy RM, Ricci JL, DiCesare PE, Rediske JJ, Abramson SB: Effects of nitric oxide on chondrocyte migration, adhesion, and cytoskeletal assembly. Arthritis Rheum 1996, 39:1905-1912.
23. Pelletier J-P, Haraoui B, Martel-Pelletier J: Modulation of cartilage degradation in arthritic diseases by therapeutic agents. In Joint Cartilage Degradation: Basic and Clinical Aspects. Edited by Woessner JF Jr, Howell DS. New York: Marcel Dekker; 1993:503-528.
24. Wright CD, Mulsch A, Busse R, Oswald H: Generation of nitric oxide by human neutrophils. Biochem Biophys Res Commun 1989, 160:813-819.
25. Charles IG, Palmer RMJ, Hickery MS, Bayliss MT, Chubb AP, Hall VS, Moss DW, Moncada S: Cloning, characterization and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A 1993, 90:11419-11423.
26. Evans CH, Stefanovic-Racic M, Lancaster J: Nitric oxide and its role in orthopaedic disease. Clin Orthop Rel Res 1995, 312:275-294.
27. Farrell AJ, Blake DR, Palmer RMJ, Moncada S: Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992, 51:1219-1222.
28. Blackburn WD: Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Am J Med 1996, 100:24S-30S.
29. Brooks PM, Day RO: Non-steroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991, 324:1716-1725.
30. Dingle JT, Shield MJ: The interactions of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair. In Advances in Prostaglandin, Thromboxane and Leukotriene Research. Edited by Samuelsson B. New York: Raven Press; 1990.
31. Kirwan JR, Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142-146.
32. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S: Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996, 39:1818-1825.
33. McDouglas R, Sibley J, Haga M, Russell A: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994, 21:1207-1213.
34. Tyler JA: Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J 1985, 227:869-878.
35. Muegge K, Oppenheim JJ: IL-1 in autoimmunity. In Molecular Autoimmunity. Edited by Talal N. London: Academic Press; 1991.
36. Saxne T, Palladino MA Jr, Heinegrad D. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988, 31:1041-1045.
37. Hopkins SJ, Humphreys M, Jayson MIV: Cytokines in synovial fluid I: the presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988, 72:422-427.
38. North J, Situnayake RD, Tikley M: Interleukin-1 beta, hand and foot bone mineral content and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 1994, 53:543-546.
39. Fernandez-Botran R: Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991, 5:2567-2574.
40. Drevlow BE, Lovis R, Haag MA: Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996, 39:257-265.
41. Pope R, Drevlow B, Capezio J: Intraarticular administration of recombinant human interleukin-1 receptor-type I in patients with active rheumatoid arthritis. Biologic Agents in Autoimmune Disease, vol IV, in press.
42. Maini RN, Elliott M, Brennan FM, et al.: Monoclonal anti-TNF-alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995, 144:195-223.
43. Elliott MJ, Maini RN, Feldmann M, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
44. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothellum by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:1082-1091.
45. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081.
46. Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 1993, 54:167-227.
47. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994, 37:644-652.
48. Arner E, Harris RR, DiMeo TM, Collins RC, WG: Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J Rheumatol 1995, 22:1338-1346.
49. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist-induced arthritis in mice. Arthritis Rheum 1993, 36:1305-1314.
50. Henderson B, Thompson RC, Hardingham T, Lewthwaite J: Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991, 3:246-249.
51. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and the IL-1 Ra Arthritis Study Group: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1092-1101.
52. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng D, Pelletier JP: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Arthritis Rheum 1996, 39:1535-1544.
53. Arend WP, J-M D: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995, 38:151-160.
54. Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, Yu C, Zvaifler NJ: IL-1 receptor antagonist protein production and gene expression in rheumatoid and osteoarthritis synovium. J Immunol 1992, 149:1054-1062.
55. Herzog C, Walker C, Müller W, Rieber P, Reiter C, Riethmüller G, Wassmer P, Stockinger H, Madic O, Pichler WJ: Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I: effect on clinical course and circulating T cells. J Autoimmun 1989, 2:627-642.
56. Choy EH, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, Kingsley GH, Panay GS: Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996, 39:52-56.
57. Choy EH, Pitzalis C, Bijl JA, Kingsley GH, Panayi GS: The importance of dose and dosing regimen of anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1993, 36(suppl 9):129.
58. Van der Lubbe PA, Eijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995, 38:1097-1106.
59. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, et al.: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995, 39:1581-1588.
60. Choy EH, Chikanza IC, Kinglsley GH, Corrigall V, Panayi GS: Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992, 36:291-298.
61. Epstein WV: Expectation bias in rheumatoid arthritis clinical trials. Arthritis Rheum 1996, 39:1773-1780. This recent review presents a very good and concise description regarding the problem of bias in general, the importance of controlled and maintained blinding process, and the importance of response criteria in clinical trials testing new therapies.
62. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990, 33:477-484.
63. Olsen NJ, Brooks RH, Lipsky PE, St-Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, et al.: A double blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1102-1108.
64. Choy EH, Kingsley GH, Panayi GS: T-cell regulation. In Innovative Treatment Approaches for Rheumatoid Arthritis. Edited by Brooks PM, Furst DE. London: Baillière Tindall; 1995:653-671.
65. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 1986, 83:7443-7446.
66. Myers LK, Stuart JM, Seyer JM, Kang AH: Identification of an immuno-suppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989, 170:1999-2010.
67. Zhang ZY, Lee CSY, Lider O, Weiner HL: Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990, 145:2489-2493.
68. Miller EJ: Biochemical characteristics and biological significance of the genetically distinct collagens. Mol Cell Biochem 1976, 13:165-192.
69. Miller A, Lider O, Weiner HL: Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991, 174:791-798.
70. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo, D, Sewell KL, Hafler DA, Weiner HL: Effects of oral administration of type II collagen on RA. Science 1993, 261:1727-1730.
71. Siaper J, Kary S, Sörensen H, Alten R, Eggens U, Huge W, Hiepe F, Kuhne A, Listing J, Ulbrich N, et al.: Oral type II collagen treatment in early RA: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39:41-51.
72. Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991, 88:2441-2445.
73. Kavanaugh AR, Davis LS, Jain RI, Nichols LA, Norris SH, Pe L: A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996, 23:1338-1344.
74. Ryan ME, Greenwald RA, Golub LM: Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1996, 8:238-247.
75. Firestein GS, Nguyen K, Aupperle K, Yeo M, Boyle DL, Zvaifler NJ: Apoptosis in rheumatoid arthritis: II: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1997, in press.
76. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS: Minocyclines reduces gingival collagenolytic activity during diabetes. J Periodontal Res 1983, 18:516-526.
77. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, Schneir M, et al.: Tetracyclines inhibit tissue collagenase activity. J Periodontal Res 1984, 19:651-655.
78. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J, Ciancio S: Further evidence that tetracyclines inhibit collagenase activity in human crevicular lung and from other mammalian sources. J Periodontal Res 1985, 20:12-23.
79. Sasaki T, Ramamurthy NS, Golub LM: Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: a quantitative autoradiographic study. Calcif Tissue Int 1992, 50:411-419.
80. Breedveld FC, Dijkmans BAC, Mattie H: Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990, 17:43-46.
81. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, et al.: Minocycline in rheumatoid arthritis: a 48-week double blind, placebo-controlled trial. Ann Intern Med 1995, 122:81-89.
82. Yu LP, Smith GN, Brandt KD, Myers SL, O'Connor BL, Brandt DA: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992, 35:1150-1159.
83. Boyle DL, Sajjadi FG, Firestein GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996, 39:923-930.
84. Firestein GS, Paine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994, 37:193-200.
85. Ialenti A, Moncada S, DiRosa M: Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 1993, 110:701-706.
86. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH: N-monomethylarginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994, 37:1062-1069.
87. Leung MK, Greenwald RA, Ramamurthy NS, Moak SA, Koszulinski R, Dieudonne D, Golub LM: Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor 4-dedimethylaminotetracycline in inflamed joints of adjuvant arthritic rats. J Rheumatol 1995, 22:1726-1732.
88. Greenwald RA, Golub L, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF: Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987, 14:28-32.